AR044599A1 - Metodo para reducir los efectos perniciosos de la nicotina administrada por via oral o transdermica - Google Patents

Metodo para reducir los efectos perniciosos de la nicotina administrada por via oral o transdermica

Info

Publication number
AR044599A1
AR044599A1 ARP040101917A ARP040101917A AR044599A1 AR 044599 A1 AR044599 A1 AR 044599A1 AR P040101917 A ARP040101917 A AR P040101917A AR P040101917 A ARP040101917 A AR P040101917A AR 044599 A1 AR044599 A1 AR 044599A1
Authority
AR
Argentina
Prior art keywords
tobacco
nicotine
reducing
transdermal
oral
Prior art date
Application number
ARP040101917A
Other languages
English (en)
Inventor
Mark Conkling
Original Assignee
Vector Tobacco Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vector Tobacco Ltd filed Critical Vector Tobacco Ltd
Publication of AR044599A1 publication Critical patent/AR044599A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
    • A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
    • A24B15/18—Treatment of tobacco products or tobacco substitutes
    • A24B15/20—Biochemical treatment
    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
    • A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
    • A24B15/18—Treatment of tobacco products or tobacco substitutes
    • A24B15/24—Treatment of tobacco products or tobacco substitutes by extraction; Tobacco extracts
    • A24B15/241—Extraction of specific substances
    • A24B15/243—Nicotine
    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
    • A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
    • A24B15/18—Treatment of tobacco products or tobacco substitutes
    • A24B15/24—Treatment of tobacco products or tobacco substitutes by extraction; Tobacco extracts
    • A24B15/241—Extraction of specific substances
    • A24B15/245—Nitrosamines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8243—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits involving biosynthetic or metabolic pathways, i.e. metabolic engineering, e.g. nicotine, caffeine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1077—Pentosyltransferases (2.4.2)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Nutrition Science (AREA)
  • Addiction (AREA)
  • Animal Behavior & Ethology (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Manufacture Of Tobacco Products (AREA)

Abstract

Reducción de los efectos perniciosos de la nicotina administrada por vía oral o transdérmica en programas convencionales para abandonar el uso del tabaco. Más específicamente, las realizaciones se relacionan con métodos para reducir los efectos perniciosos de la ingesta de nicotina asociada con los programas convencionales para abandonar el uso del tabaco, donde se administran productos basados en tabaco que contienen una cantidad reducida de nicotina y nitrosaminas específicas de tabaco (TSNA). Reivindicación 1: Un método para preparar un tabaco mixto con un bajo contenido de nicotina caracterizado porque comprende: proporcionar un primer tabaco, proporcionar un segundo tabaco producido a partir de una planta de tabaco modificada genéticamente que presenta un nivel reducido de QPTasa, en comparación con una planta de tabaco no modificada de la misma variedad, y combinar el primer y el segundo tabaco para obtener dicho tabaco con un contenido de nicotina reducido.
ARP040101917A 2003-06-04 2004-06-03 Metodo para reducir los efectos perniciosos de la nicotina administrada por via oral o transdermica AR044599A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US47594503P 2003-06-04 2003-06-04

Publications (1)

Publication Number Publication Date
AR044599A1 true AR044599A1 (es) 2005-09-21

Family

ID=33551567

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040101917A AR044599A1 (es) 2003-06-04 2004-06-03 Metodo para reducir los efectos perniciosos de la nicotina administrada por via oral o transdermica

Country Status (10)

Country Link
US (1) US20060237025A1 (es)
EP (1) EP1628681A4 (es)
JP (1) JP2007528204A (es)
KR (1) KR20060032141A (es)
CN (1) CN1812811A (es)
AR (1) AR044599A1 (es)
AU (1) AU2004251635A1 (es)
CA (1) CA2527648A1 (es)
WO (1) WO2005000352A1 (es)
ZA (1) ZA200510170B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006247739A1 (en) 2005-05-11 2006-11-23 Vector Tobacco Inc. Reduced risk tobacco products and methods of making same
MX2009012842A (es) 2007-06-01 2009-12-11 Syngenta Participations Ag Metodos para la produccion comercial de plantas transgenicas.
US7665472B2 (en) * 2007-11-06 2010-02-23 Alliance One International, Inc. Tobacco cultivar AOB 175 and products therefrom
US7667106B2 (en) 2007-11-06 2010-02-23 Alliance One International, Inc. Tobacco cultivar ‘AOB 175’
WO2010046422A2 (en) 2008-10-22 2010-04-29 Basf Se Use of auxin type herbicides on cultivated plants
WO2010046423A2 (en) 2008-10-22 2010-04-29 Basf Se Use of sulfonylurea herbicides on cultivated plants
JP2015532274A (ja) 2012-10-01 2015-11-09 ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ 栽培植物へのｎ−チオ−アントラニルアミド化合物の使用
WO2014079820A1 (en) 2012-11-22 2014-05-30 Basf Se Use of anthranilamide compounds for reducing insect-vectored viral infections
CN103005702B (zh) * 2012-12-12 2015-03-18 广东中烟工业有限责任公司 一种深度抽吸下基于危害性指数的低危害卷烟设计方法
CN102940310B (zh) * 2012-12-12 2015-08-05 广东中烟工业有限责任公司 一种基于n-亚硝胺释放量的卷烟设计中各个组分的调整方法
CN103005703B (zh) * 2012-12-12 2015-04-15 广东中烟工业有限责任公司 一种基于烟气危害性指数的卷烟设计方法
EP3028573A1 (en) 2014-12-05 2016-06-08 Basf Se Use of a triazole fungicide on transgenic plants
WO2016091674A1 (en) 2014-12-12 2016-06-16 Basf Se Use of cyclaniliprole on cultivated plants
CA2980505A1 (en) 2015-04-07 2016-10-13 Basf Agrochemical Products B.V. Use of an insecticidal carboxamide compound against pests on cultivated plants
EP3338552A1 (en) 2016-12-21 2018-06-27 Basf Se Use of a tetrazolinone fungicide on transgenic plants
JP7244024B2 (ja) * 2018-06-25 2023-03-22 学校法人近畿大学 ニコチン摂取の影響による血管壁のコラーゲン分解防止剤
US20230399651A1 (en) * 2019-10-10 2023-12-14 Altria Client Services Llc Compositions and Methods Based on QPT Engineering for Producing Tobacco Plants and Products Having Altered Alkaloid Levels
CN113528537A (zh) * 2021-08-11 2021-10-22 云南省烟草农业科学研究院 一种降低烟叶烟碱含量的NtQPT2基因突变体及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993005646A1 (en) * 1991-09-13 1993-04-01 Technology Management Services, S.A. Reduction of nicotine levels in tobacco
AU4991500A (en) * 1999-05-06 2000-11-21 Michael Timko Regulation of gene expression in tobacco for manipulation of plant growth and secondary metabolism
CA2399376A1 (en) * 2000-02-07 2001-08-16 Cristobal Guillermo Dos Remedios Biomolecular toxicity assay
EP1313868B1 (en) * 2000-08-30 2006-07-19 North Carolina State University Transgenic plants containing molecular decoys that alter protein content therein
AU2002228901A1 (en) * 2000-11-10 2002-05-21 Vector Tobacco (Bermuda) Ltd. Method and product for removing carcinogens from tobacco smoke
US20060157072A1 (en) * 2001-06-08 2006-07-20 Anthony Albino Method of reducing the harmful effects of orally or transdermally delivered nicotine
NZ530238A (en) * 2001-06-08 2004-08-27 Vector Tobacco Ltd Modifying nicotine and nitrosamine levels in tobacco
AU2002340407A1 (en) * 2001-11-09 2003-05-26 Vector Tobacco Inc. Method and composition for mentholation of charcoal filtered cigarettes
JP2005522201A (ja) * 2002-04-09 2005-07-28 ベクター、タバコ、リミテッド ニコチンおよびニトロソアミンを減少させたタバコ
US20050066986A1 (en) * 2003-09-30 2005-03-31 Nestor Timothy Brian Smokable rod for a cigarette

Also Published As

Publication number Publication date
KR20060032141A (ko) 2006-04-14
EP1628681A1 (en) 2006-03-01
CA2527648A1 (en) 2005-01-06
EP1628681A4 (en) 2009-07-15
JP2007528204A (ja) 2007-10-11
ZA200510170B (en) 2006-11-29
AU2004251635A1 (en) 2005-01-06
WO2005000352A1 (en) 2005-01-06
US20060237025A1 (en) 2006-10-26
CN1812811A (zh) 2006-08-02

Similar Documents

Publication Publication Date Title
AR044599A1 (es) Metodo para reducir los efectos perniciosos de la nicotina administrada por via oral o transdermica
JP2017501714A (ja) 電子タバコ用液体組成物
AR060931A1 (es) Producto farmaceutico recubierto para la administracion intraoral de nicotina y su uso y elaboracion
DK1458252T3 (da) Tobak og/eller tobak i kombination med tobakssubstitutkomposition til anvendelse som snus i den orale kavitet
HUP0400161A2 (hu) Módosított nikotin- és nitrozamintartalmú dohány
AP1510A (en) Smokeless tobacco product.
RU2014134073A (ru) Пероральный продукт
US9538782B2 (en) Inhibition of sensory irritation during consumption of smokeless tobacco products using a combinatorial approach
BRPI0413733A (pt) produtos de tabaco com exposição reduzida
NO20084992L (no) Farmasoytisk produkt for intraoral avlevering av nikotin innbefattende trometamol som bufringsmiddel
AR047141A1 (es) Articulo para fumar
AR044383A1 (es) Composiciones farmaceuticas de vareniclina
US20050034738A1 (en) Chewing tobacco substitute containing nicotine
BR112022023812A2 (pt) Composição de bolsa de nicotina oral sem tabaco
KR102038342B1 (ko) 니코틴 제형
KR101257828B1 (ko) 다마스콘 함유 금연보조제 조성물
Sharma et al. Novel pathways and mechanisms of Nicotine-Induced oral carcinogenesis
US20060112965A1 (en) Chewing tobacco substitute containing cotinine
DE502004002023D1 (de) Tabakmischung, sowie eine diese enthaltende cigarette
Sintija et al. The oral microbiome of smokeless tobacco users in Latvia
FI127620B (fi) Nuuskantyyppinen nikotiini-pellavansiemenrouhekoostumus
ISMAIL et al. Electronic Cigarettes and Oral Health: A Narrative Review.
Ramachandran et al. Activation of platelets exposed to shear stress in the presence of smoke extracts of low-nicotine and zero-nicotine cigarettes: the protective effect of nicotine
Viegas Noncigarette forms of tobacco use
Alkhlaif et al. Assessment of abuse-related discriminative stimulus effects of nicotine aerosol in rodents

Legal Events

Date Code Title Description
FA Abandonment or withdrawal